Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
about
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trialIntravital FRET imaging of tumor cell viability and mitosis during chemotherapyPharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complexDesign, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy.Adjuvant effect of docetaxel on the immune responses to influenza A H1N1 vaccine in mice.Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.Preclinical profile of cabazitaxel.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminaseTetrandrine induces mitochondria-mediated apoptosis in human gastric cancer BGC-823 cells.Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.Design, synthesis, and biological evaluation of theranostic vitamin-linker-taxoid conjugatesCore-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical TranslationA phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.Encapsulation of docetaxel in oily core polyester nanocapsules intended for breast cancer therapyDisposition kinetics of taxanes in peritoneal disseminationTau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer.Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerPhase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyDocetaxel for the post-surgery treatment of patients with node-positive breast cancerFluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery.Antitumor activity of docetaxel-loaded polymeric nanoparticles fabricated by Shirasu porous glass membrane-emulsification technique.Taxane anticancer agents: a patent perspective.Photoswitchable nanoparticles for in vivo cancer chemotherapyCarcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo.Strategic Incorporation of Fluorine into Taxoid Anticancer Agents for Medicinal Chemistry and Chemical Biology Studies.Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate.In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells.Radiosensitizing Silica Nanoparticles Encapsulating Docetaxel for Treatment of Prostate Cancer.
P2860
Q24799659-E45BCFAB-306B-4383-84A5-90CAD0EE6208Q27319918-3AC81971-894F-444A-8F7C-0F9B640427FEQ28742710-CD481821-F814-45A5-B256-15C2A203D71BQ33894592-91D3FCBF-3951-4BE2-B136-6E46F6B3A004Q34329446-D18B1452-1F98-48F4-AFAC-71C8E85E03E8Q34379034-7F5B0920-9179-476C-BC9D-360BB65FB1CCQ34394251-91DC627C-93D7-4A95-9C2E-1F9398328FABQ34447986-15EACC98-6D15-47F6-8FF6-1B588010710EQ34468009-B896541D-80AB-4534-92C9-B7882A4C9888Q35009473-A11542E2-BD98-4DA8-8C70-90CE37BB474AQ35045144-FE95E325-0AA9-4850-BDAA-4F0B9A1A3251Q35175462-C2C3135F-A800-467D-AB31-A91326DEE8CCQ35438759-9A4A11F4-6F0C-4C74-9747-B577AD670614Q35783841-16C54E53-71F3-446C-971E-2C826D4109A6Q35798402-F0366379-E875-49DF-8E0C-5D9AFBBAD5DAQ35994258-579C0462-6A88-418A-A0B3-38E6C1C9C0A8Q36115489-D6947CF3-15B4-492B-AFC1-D4AD5794F739Q36297024-C24E77A2-4D9D-46D0-93D2-1CA261B9BC1DQ36520778-5198E56B-BD5E-48EC-A231-75AD8078FA0FQ36614337-094F06FD-EFEA-4211-9EED-A5E3F0E6B7F6Q36614394-A01C4576-AEBC-42F4-8070-AC6067EC1C29Q36615520-33C1D1AC-6EE6-4801-9951-4A0B1DA4F609Q36642245-F399A5E1-AF1E-46B2-BBBC-E0C85274801FQ36646250-99CF010F-F899-4763-A1EF-9878EA6C91DBQ36649028-552E4E37-846E-4299-9E1B-70A86B1E4970Q36667443-31E11C45-D88D-4B3D-BBEA-52ABFA5BDAEFQ36823602-6C85DC12-F37F-44F6-92CA-67788FA48050Q37074780-27BE3220-C62B-4DDB-B5EE-A08DCC2C349BQ37074891-5FF457E3-6722-456D-8CE1-29D6035A487FQ37087888-17414621-52AD-48FD-AEF2-588905430F2AQ37340860-192E75FC-652E-4EE4-9578-58C73F57841FQ37535233-EE337030-BD98-45E8-9BC5-66E2A955BC43Q38694536-8AF2EAE2-6C28-4B7A-8AE9-0B2303797DD4Q38695277-CEA02870-BEF8-4E15-A920-7D7B4AE3DB8BQ38896408-F1ED080D-C10E-4784-9D85-C67339D72C57Q40105899-3E5A04E9-5B34-46DA-8AD7-A15588B95DDCQ41154167-0B691A0B-9665-4C6E-A949-990F0D0EC31A
P2860
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Docetaxel (Taxotere): a review ...... art I: Preclinical experience.
@en
type
label
Docetaxel (Taxotere): a review ...... art I: Preclinical experience.
@en
prefLabel
Docetaxel (Taxotere): a review ...... art I: Preclinical experience.
@en
P2093
P1433
P1476
Docetaxel (Taxotere): a review ...... art I: Preclinical experience.
@en
P2093
G J Sanderink
M C Bissery
P304
339-55, 363-8
P577
1995-06-01T00:00:00Z